Title
Comparative lineage tracing reveals cellular preferences for prostate cancer initiation.

Permalink
https://escholarship.org/uc/item/6zw4547n

Journal
Molecular & cellular oncology, 2(3)

ISSN
2372-3556

Authors
Wang, Zhu A
Shen, Michael M

Publication Date
2015-07-01

DOI
10.4161/23723556.2014.985548

Peer reviewed
Comparative lineage tracing reveals cellular preferences for prostate cancer initiation

Zhu A Wang1,* and Michael M Shen2,*

1Department of Molecular Cell & Developmental Biology; University of California, Santa Cruz, CA USA; 2Departments of Medicine, Genetics and Development, Urology, and Systems Biology; Columbia Stem Cell Initiative; Herbert Irving Comprehensive Cancer Center; Columbia University College of Physicians and Surgeons, New York, NY USA

Keywords: cell of origin, mouse models, prostate cancer, tumor initiation

The cell of origin for cancer is defined as a normal tissue cell that is targeted by oncogenic events and is transformed to give rise to a tumor. Over the past few years, there has been increasing evidence to support a model in which cancer subtypes with distinct histopathological features or patient outcomes may originate from different cell types of origin within a given tissue.1 Therefore, because of the significant implications of understanding the cell of origin for facilitating patient stratification and personalized treatment, identification of the cells of origin for cancer has received considerable interest.

In the normal untransformed prostate, basal cells and luminal cells represent the two major epithelial cell types. However, human prostate adenocarcinomas all display luminal features, and in fact are diagnosed on the basis of the absence of basal cells. Nonetheless, it has been quite controversial whether basal or luminal cells, or both, represent the cells of origin for prostate cancer. For example, previous studies have isolated human prostate basal or luminal cells followed by their transduction with oncogenes and found that only the basal population could support tumor formation in renal grafts in immunodeficient mice, suggesting basal cells as the cell of origin.2,3

A major caveat of the renal grafting approach is that cancer initiation and progression does not occur in the context of a native tissue environment. To overcome this limitation, we and others have utilized genetic lineage tracing and conditional deletion of the Pten tumor suppressor gene specifically in basal or luminal cells of the mouse prostate, and showed that both basal and luminal cells could serve as cell types of origin for prostate cancer in vivo.4-6 Interestingly, tumors originating from basal cells displayed luminal phenotypes since transformed basal cells rapidly differentiated into luminal cells, which then propagated the luminal features of prostate cancer. However, despite their similar end-stage histopathology, luminal-derived mouse tumors progressed more rapidly than basal-derived tumors and had a distinct molecular profile that correlates with more aggressive phenotypes in human patients.7

These findings led us to investigate whether luminal cells might be more susceptible to oncogenic transformation in vivo. Furthermore, we were interested in determining whether different oncogenic drivers might affect the ability of a given cell type to serve as a cell of origin. Therefore, to test which cell type(s) is favored as the cell of origin for prostate cancer in response to distinct oncogenic drivers, we performed comparative lineage tracing of basal or luminal cells in a diverse range of genetically engineered mouse models of prostate cancer.7

Unlike previous cell-of-origin studies in which oncogenic drivers were introduced specifically into cell types of interest, we took the converse approach of expressing the oncogenic drivers throughout the prostate epithelium, followed by determination of whether the basal or luminal cells had generated tumor lesions. For this purpose, we used mouse models in which tumor formation was driven by Myc overexpression (Hi-Myc mice), inactivation of the Nkx3–1 and Pten tumor suppressors, inactivation of the Trp53 and Rb1 pathways by SV40 T antigen (TRAMP mice), and elevated levels of androgen and estrogen hormones, all of which can drive human prostate tumorigenesis.8 To determine the cell type of origin in each mouse model, we lineage marked basal or luminal cells in histologically normal prostate prior to tumor formation and then investigated whether marked cell clusters were present in the tumors that subsequently arose. Notably, we found that luminal cells were consistently the observed cell of origin in all of the models tested.

Our results strongly support the notion that luminal cells are more prone to
oncogenic transformation than basal cells and are the favored cell type of origin in the endogenous prostate tissue environment. One potential caveat is that the genetically engineered models used for our study express oncogenic events throughout the prostate epithelium, rather than in a smaller subset of cells. However, since the oncogenic stimuli indiscriminately affected both basal and luminal cells, we could directly compare their susceptibility to oncogenic transformation in a controlled manner. Furthermore, the hormonal carcinogenesis model does not rely on any genetically engineered oncogenic event, and provides unequivocal evidence for luminal cells as the preferred cell of origin. Although our conclusions differ from those of Witte and colleagues, the experimental data from these studies are consistent. In particular, when we isolated the basal cells from our mouse models and performed renal grafts in immunodeficient nude mice, the grafted cells readily generated prostate tissue with tumor phenotypes. Therefore, both normal and transformed basal cells demonstrate significant plasticity when removed from their endogenous tissue environment. 

One model to explain our findings utilizes the concept of “cell of mutation” that was first proposed in studies of the cell of origin for glioma. In this view, basal cells carrying oncogenic events display plasticity by acquiring progenitor properties in renal grafts and behave as cells of mutation, generating progeny luminal cells that are authentic cells of origin. A recent report showing that prostate cancer can be derived from basal cells in renal grafts and then propagated by luminal cells is consistent with this model. In particular, since the renal graft assay involves generation of prostate tissue from a small number of dissociated cells, a process analogous to prostate organogenesis, this assay may not accurately indicate true cell types of origin, which only reside in the adult prostate (Fig. 1).

It should be noted that our finding that luminal cells are favored as cells of origin in the mouse models examined does not exclude the possibility that basal cells are cells of origin for different models or for distinct tumor subtypes. Previous lineage tracing studies have shown that adult basal cells have the capability to initiate cancer in situ and may be responsible for a less malignant subtype of human prostate cancers. This raises the question of why we did not observe any tumors with a basal cell of origin. One possibility is that such tumors might be observed in experimental contexts using different oncogenic drivers. Alternatively, another possibility is that transformed luminal cells can out-compete transformed basal cells and their growth into tumors in a non-cell-autonomous manner.

In conclusion, our work complements prior lineage tracing studies, and together with previous work provides a clearer understanding of the cell types of origin for prostate cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgment

We apologize to colleagues whose work was not discussed due to space constraints.

Funding

ZAW is supported by UCSC startup funds and CIRM. MMS is supported by grants from the NIH.

References

1. Blanpain C. Tracing the cellular origin of cancer. Nat Cell Biol 2013; 15:126-34; PMID:23334500; http://dx.doi.org/10.1038/nclcb2657
2. Golstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science 2010; 329:568-71; PMID:20671189; http://dx.doi.org/10.1126/science.1189992
3. Taylor RA, Tovianen R, Frydenberg M, Pedersen J, Harwood L, Australian Prostate Cancer B, Collins AT, mainland NJ, Ruhbridger GP. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells 2012; 30:1087-96; PMID:22593016; http://dx.doi.org/10.1002.stem.1094
4. Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A, Shen MM. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol 2013; 15:274-83; PMID:23434823; http://dx.doi.org/10.1038/nclcb2697
5. Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. Am J Pathol 2015; 187:1374-83; PMID:26214130; http://dx.doi.org/10.1016/j.amjpathol.2015.08.019
6. Choi N, Zhang B, Zhang L, Ittmann M, Xin L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 2012; 21:253-65; PMID:22340597; http://dx.doi.org/10.1016/j.ccr.2012.01.005

7. Wang ZA, Toivanen R, Bergren SK, Chambon P, Shen MM. Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep 2014; 8:1339-46; PMID:25176651; http://dx.doi.org/10.1016/j.celrep.2014.08.002

8. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24:1967-2000; PMID:20884812; http://dx.doi.org/10.1101/gad.1965810

9. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, Nishiyama A, Luo L, et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011; 146:209-21; PMID:21737130; http://dx.doi.org/10.1016/j.cell.2011.06.014

10. Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Piera KJ, Zhang H, Kohn DB, Huang J, Witte ON, et al. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A 2013; 110:20111-6; PMID:24282295; http://dx.doi.org/10.1073/pnas.1320565110